T-cell Lymphomas Biology and Management

Size: px
Start display at page:

Download "T-cell Lymphomas Biology and Management"

Transcription

1 T-cell Lymphomas Biology and Management March

2 Outline Epidemiology Initial Work-up International Prognostic Index Treatment of Diffuse Large B-cell Lymphoma: -Limited Stage -Advanced Stage Frontline: R-CHOP Relapse: PARMA, CORAL CNS prophylaxis PMBCL Testicular Lymphoma Paranasal Sinus Lymphoma

3 NHL Etiology Immune deficiency (Congenital or Acquired) Autoimmune disorders (e.g. Hashimoto s thyroiditis, Sjogren s syndrome, RA) Infectious agents HIV Helicobacter pylori (infection of stomach and MALT) EBV, Human T-cell leukemia virus, KS-associated Herpes virus Chemical and physical agents (e.g. pesticides) Dietary

4 Epidemiology

5 Non-Hodgkin Lymphoma PMLBCL 3% MZL-NT 1% ALCL 2% BL 2% PTCL 7% MALT 6% DLBCL 36% MCL 7% SLL 7% FL 26% ALCL = Anaplastic large cell lymphoma, BL= Burkitt s lymphoma, DLBCL = diffuse large B-cell lymphoma, FL = Follicular lymphoma, SLL = small lymphocytic lymphoma, MCL = Mantle cell lymphoma, MZL-NT = Nodal marginal zone lymphoma, PTCL = Peripheral T-cell lymphoma, MALT = Mucosa-associated lymphoid tissue, PMLBCL = Primary mediastinal large B-cell lymphoma. JCO 1998

6 WHO Classification (2016) of Lymphoid Neoplasms Swerdlow. Blood 2016 * Change from 2008

7 WHO Classification Peripheral T-cell Lymphoma Predominantly Nodal Peripheral TCL, NOS Angioimmunoblastic TCL Anaplastic large cell lymphoma, ALK+ Anaplastic large cell lymphoma, ALK- Predominantly Extranodal NK/T-cell lymphoma, nasal/ type Enteropathy-associated TCL Hepatosplenic TCL EBV+ T-cell LPD of childhood Predominantly Leukemic T-cell prolymphocytic leukemia T-cell LGL leukemia Chronic LPD of NK cells Aggressive NK-cell leukemia Adult T-cell leukemia/lymphoma Predominantly Cutaneous Mycosis Fungoides Primary cutaneous CD30+ T-cell LPD Primary cutaneous peripheral TCL Sezary syndrome Subcutneous Panniculitis-like TCL Primary cutaneous CD8+ cytotoxic TCL Primary cutaneous small/medium CD4+ TCL

8 PTCL

9 Initial Workup History and Physical: B symptoms LN Biopsy : excisional, core, FNA Laboratory: CBC, Chem, LDH HIV CT scans C/A/P with contrast PET scan Bone Marrow Biopsy: Flow, IHC, FISH, Cytogenetics MUGA, Echocardiogram MRI, LP if indicated B symptoms: Fever, drenching night sweats, > 10% unintentional weight loss in 6 months

10 Costwolds Modification of Ann Arbor Staging System PET PET/CT

11 Peripheral T-cell Lymphoma Heterogeneous group PTCL 10% of NHL Prognosis: - 5 year OS < 30% Untreated PTCL: CHOP, CHOEP ASCT in CR1 PTCL-NOS

12 Chromosomal translocations in NHL T(14;18)(q32;q21) T(11;18)(q21;q21) T(14;18)(q32;q21) T(1;14)(q22;q32) T(3;14)(p14.1;q32) T(11;14)(q13;q32) T(3;14)(q27;q32) T(14;18)(q32;q21) T(2;5)(p23;q35) Follicular Lymphoma MALT Lymphoma MALT Lymphoma MALT Lymphoma MALT Lymphoma Mantle cell Lymphoma DLBCL DLBCL ALCL, ALK+

13 Anaplastic Large cell Lymphoma t(2;5)(p23;q35) ALK Chromosome 2q23 Novel tyrosine kinase NPM Chromosome 5q35 Involved in ribosomal assembly Mechanism NPM-ALK fusion protein autophosphorylates the tyrosine kinase domain of ALK Incidence 40-60% of anaplastic large cell lymphomas

14 Anaplastic Large Cell Lymphoma

15 Anaplastic Large Cell Lymphoma

16 NPM/ALK Translocation

17 ALK Fusion Proteins in ALK+ ALCL Falini B. Br J Haematol Sep;114(4):

18 T-cell subtypes Registry PTCL NOS AITL ALCL, ALK + ALCL, ALK NK/T ATL EATL IPTCL (NA) 34% 16% 16% 8% 5% 2% 6% BCCA 59% 5% 6% 9% 9% NA* 5% COMPLETE 34% 15% 11% 8% 6% 2% 3% Vose JM, et al. J Clin Oncol. 2008;26: Savage, K.J., et al.. Ann Oncol, (10): Foss, F.M., et al., Blood, (21).

19 International Prognostic Index IPI (APLES): -Age > 60 -Performance Status 2 -LDH > ULN -Extranodal sites > 1 -Stage III-IV Risk model No. of factors Distribution of cases (%) 5-year OS (%) CR rate (%) Low Low-intermediate High-intermediate High The International Non-Hodgkin s Lymphoma Prognostic Factors Project. N Engl J Med1993; 329:

20 PFS in PTCL: Swedish National Registry ALK+ ALCL TCL U ALK ALCL ALK U ALCL AITL PTCL NOS Fredrik Ellin et al. Blood 2014;124:

21 Question 1 For a fit patient with newly diagnosed PTCL, in the absence of a clinical trial, what is your preferred initial treatment approach? 1. CHOP 2. CHOEP 3. EPOCH 4. CHOEP or EPOCH-HDT-ASCT 5. CHOEP or EPOCH-Allo SCT 6. Something else

22 CHOP Based Treatment for Mature T Cell and NK Cell Lymphomas Always Anaplastic Large Cell ALK 1 positive Never Mycosis fungoides Sezary syndrome Sometimes Peripheral T cell lymphoma NOS AngioimmunoblasticT cell lymphoma Anaplastic Large Cell ALK 1 positive Enteropathy type intestinal lymphoma Subcutaneous panniculitis like T cell Primary cutaneous CD30+ disorders Anaplastic large cell lymphoma Lymphomatoid papulosis T cell large granular lymphocytic Extranodal NK /T cell lymphoma nasal Hepatosplenic T cell lymphoma NK /T cell leukemia / lymphoma AdultT cell leukemia / lymphoma T cell prolymphocytic leukemia

23 Patients (%) Patients (%) Patients (%) Adding Etoposide to CHOP: German Prospective High-Grade NHL Studies Etoposide (n = 34) 80 6 x CHOEP-14/21 (n = 42) x CHOP-14/21 (n = 41) EFS, aged < 60 yrs Non-etoposide (n = 12) EFS, ALCL, ALK+ 20 P = Mos PTCL Subtype n ALCL, ALK+ 78 ALCL, ALK 113 PTCL NOS 70 AITL 28 Other 31 Total P =.057 P =.012 Etoposide (n = 69) Non-etoposide (n = 29) Mos Mos EFS, other subtypes Schmitz N, et al. Blood. 2010;116:

24 ALCL: OS based on genetic subtype Parrilla Castellar E R et al. Blood 2014;124:

25 Prognosis by Interim PET PFS by Interim PET ASCT ITT; PFS by Interim PET/IPI N=61 % EFS CR IPI 0-2 CR IPI >2 No CR IPI 0-2 No CR - High IPI >2 2 yrs 3 yrs 5 yrs Casulo et al., Leukemia & Lymphoma 2013; 54(10): Mehta et al. Clin Leuk Lym 2013;13(6):664 70

26 Brentuximab vedotin (BV) Beyond Relapsed ALCL PTCL (Relapsed) 1 Best Clinical Response Overall Response CR n (%) PR n (%) SD n(%) PD n (%) CR + PR n (%) Mature T /NK cell (n=34) 8 (24) 6 (18) 6 (18) 14 (41) 14 (41) AITL (n=13) 5 (38) 2 (15) 3 (23) 3 (23) 7 (54) PTCL NOS (n=21) 3 (14) 4 (19) 3 (14) 11 (52) 7 (33) Front Line: BV + cyclophosphamide, doxorubicin and prednisone (CHP) 2 ALCL N (%) Other N (%) Total N (%) PFS N=26 Median F/U 21.4 mos Est 1 yr PFS 71% ORR 19 (100) 7 (100) 26 (100) CR 16 (84) 7 (100) 23 (88) PR 3 (16) -- 3 (12) 1. Horwitz S M et al. Blood 2014;123: Fanale et al JCO 2014: ;

27 Question 2 For a fit patient with relapsed PTCL, in the absence of a clinical trial, what is your preferred initial treatment approach? 1. ICE or DHAP-ASCT 2. Single agent until progression 3. ICE or DHAP-Allo SCT 4. Single agent followed by Allo

28 Autologous stem cell transplantation as first line therapy in PTCL 166 pts enrolled Histologies: PTCL NOS (39%) Alk- ALCL (19%) AITL (19%) EATL Outcomes, (13%) % 5-year PFS 44% Induction: CHOEP x pts autohct Results: 5 yr PFS and OS = 51% Median Follow-up of 10 years Alk- ALCL has best survival All Patients, ITTP ALK-negative ALCL N= 160 N=31 PFS by histology OS PFS Gisselbrecht C et al. J Clin Oncol Sep 20;28(27):

29 HSCT for PTCL Autologous HSCT more efficacious in early disease CR1 pts have better outcomes compared to >CR1 pts Moderately better PFS/OS than population based series with CHOP 30-50% pts do not reach transplant mainly due to PD Does autosct as consolidation improve results or just selecting for healthier people with chemosensitive disease? Myeloablative allogeneic SCT associated with high TRM Reduced intensity conditioning promising Histologies to consider for allosct in CR1/PR1 Hepatoplenic T cell Enteropathy associated T cell Gamma delta T cell

30 Relapsed/Refractory PTCL

31 Autologous Transplantation in Relapsed PTCL CIBMTR: PFS excluding pt in CR1 (Most patients ALCL) The Stanford Experience Auto MSKCC 1.0 Median PFS 6 months % PFS ICE months Response to ICE 70% (28/40) Received ASCT 68% (27/40) Benefits are unclear. Most single institution studies show low PFS rates while registry data suggests better outcomes Smith S, et al. JCO September 1, 2013 vol. 31 no Chen AI, et al. Biol Blood MarrowTransplant. 2008;14(7): Horwitz et al, ASHAnnual Meeting Abstracts 2005;106:

32 Allogeneic Transplantation in T-cell lymphoma N=65 2Year OS: 59% 2Year PFS: 48% Median PFS mo N. Mehta Shah et al ASH 2015

33 FDA approved Agents for TCL Overall Response Rate (%) Philip T, et al. N Engl J Med Dec 7;333(23):1540-5

34 FDA approved Agents for TCL Subtype Pralatrexate Romidepsin Belinostat Brentuximab vedotin PTCL, NOS AITL ALCL O Connor OA, et al. J Clin Oncol. 2011;29: Coiffier B, et al. J Clin Oncol. 2012;30: O Connor OA et al, ASCO 2013; Horwitz, S et al ICML 2013 Pro B, et al. J Clin Oncol. 2012;30: Horwitz S M et al. Blood 2014;123:

35 Brentuximab vedotin (BV) Relapsed ALCL ORR= 86% CR= 57% Pro B et al. J Clin Oncol Jun 20;30(18):2190-6

36 Anaplastic Large-Cell Lymphoma

37 Question #1 A 43-year-old man presents with cervical adenopathy. Evaluation of a biopsy specimen indicates anaplastic large cell lymphoma. Neoplastic cells are positive for CD30 and ALK but negative for CD20 and PAX5. Staging studies show stage IV disease with bone marrow involvement.

38 Question #1 (continued) Which of the following markers is the most likely to be associated with better outcome in this patient? Expression of ALK Expression of CD30 Lack of CD20 expression Lack of t(2;5) Lack of PAX5 expression

39 Explanation Anaplastic large-cell lymphoma is a distinct clinical entity and is composed of large anaplastic cells expressing CD30. B-cell markers such as CD20 and PAX5 are absent. CD30, although an important marker in the diagnosis and treatment of relapsed disease (with brentuximab vedotin), is not prognostic. However, ALK-positive anaplastic large-cell lymphoma is associated with excellent outcomes when treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), with the majority of patients cured from the disease, even patients with high-stage disease according to the international prognostic index. ALK expression is associated with a characteristic chromosomal translocation, t(2;5)(p23;q35), resulting in a fusion gene, NPM-ALK, encoding a chimeric protein with tyrosine kinase activity. Hence, the presence of t(2;5) is a marker of ALK positivity and is associated with a good prognosis. In contrast, the outcomes for patients with ALK-negative anaplastic large-cell lymphoma are poor and similar to those for patients with peripheral T-cell lymphoma.

40 Peripheral T Cell Lymphoma

41 Question #1 A 52-year-old man with a history of well-controlled hypertension presents with progressive sweats over the past 3 months associated with a 10-lb (4.5- kg) weight loss. Initial evaluation is notable for bilateral axillary and left inguinal adenopathy. Evaluation of the left inguinal lymph node, obtained with excisional biopsy, indicates diffuse proliferation of medium-to-large cells that are positive for CD2, CD3, and CD4 but negative for CD7 and ALK. The large cells stain brightly for CD30. Computed tomography images of the chest, abdomen, and pelvis show lymph nodes on both sides of the diaphragm, with the largest ones measuring 2 to 3 cm. Evaluation of a bone marrow biopsy sample indicates normal trilineage hematopoiesis without lymphoma. Results from laboratory studies, including a complete blood cell count and chemistry panel, are within normal parameters. A serum lactate dehydrogenase level is nearly twice the upper limit of normal

42 Question #1 (continued) Which of the following is the best treatment for this patient? Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) Brentuximab vedotin plus CHOP Cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (CHOEP) Anthracycline-based chemotherapy plus a consolidative allogeneic stem cell transplant

43 Explanation The patient in this clinical scenario has a nodal peripheral T-cell lymphoma (PTCL). On the basis of the available histology and immunophenotypic markers, he most likely has ALK-negative anaplastic large-cell lymphoma (ALCL) or PTCL not otherwise specified (NOS) with associated CD30 + expression. ALCL is a type of PTCL that may or may not be associated with ALK expression due to t(2;5) rearrangement. ALK-negative ALCL is characterized by sheets of monomorphic CD30 + T cells without ALK expression but is histologically identical to ALK-positive ALCL. Patients with ALK-positive ALCL tend to be younger and have a more favorable outcome than patients with ALK-negative ALCL. PTCL-NOS is a provisional category in the 2008 World Health Organization classification that is likely to be further subdivided as advances in gene expression profiling and other molecular techniques refine our ability to identify subgroups. ALK-negative ALCL can often be difficult to distinguish from PTCL-NOS, which can have CD30 + overexpression in more than half of cases.

44 Explanation (continued) Given the lack of large prospective trials in the frontline setting, initial management of T-cell lymphomas is based on the aggregate experience with aggressive B-cell lymphomas, in which the standard backbone is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Unfortunately, CHOP is not nearly as effective in T-cell histologies, with only one-third of patients remaining progression-free 1 year after treatment. Because of these suboptimal outcomes with CHOP, two approaches include the incorporation of etoposide into frontline treatment (CHOEP) and the inclusion of consolidative autologous, not allogeneic, stem cell transplantation. The use of CHOEP as frontline management for young patients comes from an unplanned analysis of patients included in prospective trials of CHOP vs CHOEP by German cooperative groups. In these studies, the addition of etoposide was associated with a progression-free survival benefit for patients younger than 60 years of age. Prospective data also support the safety and feasibility of CHOEP followed by consolidative autologous hematopoietic cell transplant. Although there are no comparative data for autologous hematopoietic cell transplant vs chemotherapy alone, the findings of several phase 2 trials suggest an improved progression-free and overall survival. Consolidative allogeneic stem cell transplant remains investigational. Brentuximab vedotin is an antibody-drug conjugate approved for use in patients with relapsed ALCL, Hodgkin lymphoma, and other CD30 + T-cell lymphomas. It is being tested in frontline regimens. However, because the major toxicity is peripheral neuropathy, a large ongoing trial uses brentuximab vedotin to replace vincristine, which is being compared with CHOP.

Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center

Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Some but not as many

More information

Controversies and Approaches to T cell Lymphoma Therapy in 2016

Controversies and Approaches to T cell Lymphoma Therapy in 2016 Controversies and Approaches to T cell Lymphoma Therapy in 2016 Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Associate Professor of Medicine Weill

More information

Changing the landscape of treatment in Peripheral T-cell Lymphoma

Changing the landscape of treatment in Peripheral T-cell Lymphoma Changing the landscape of treatment in Peripheral T-cell Lymphoma Luis Fayad Associate Professor MD Anderson Cancer Center Department of Lymphoma and Myeloma 1 6 What is peripheral 2008 WHO CLASSIFICATION

More information

What is the best approach to the initial therapy of PTCL? standards of treatment? Should all

What is the best approach to the initial therapy of PTCL? standards of treatment? Should all What is the best approach to the initial therapy of PTCL? standards of treatment? hould all Jia Ruan, M.D., Ph.D. Center for Lymphoma and Myeloma Weill Cornell Medical College New York Presbyterian Hospital

More information

Change Summary - Form 2018 (R3) 1 of 12

Change Summary - Form 2018 (R3) 1 of 12 Summary - Form 2018 (R3) 1 of 12 Form Question Number (r3) Type Description New Text Previous Text Today's date was removed 2018 N/A Today's Date Removed from Key Fields 2018 N/A HCT Type 2018 N/A Product

More information

Updates in T cell Lymphoma

Updates in T cell Lymphoma Winship Cancer Institute of Emory University Updates in T cell Lymphoma Mary Jo Lechowicz August 2014 Objectives Update current care for patients with Peripheral T cell Non Hodgkin lymphomas (PTCL) upfront

More information

PET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be

PET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be PET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, DC, USA So What is the Question(s)? What is

More information

Aggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre

Aggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre Aggressive Lymphomas - Current Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre Conflicts of interest I have no conflicts of interest to declare Outline What does aggressive lymphoma

More information

Lymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital

Lymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital Lymphoma/CLL 101: Know your Subtype Dr. David Macdonald Hematologist, The Ottawa Hospital Function of the Lymph System Lymph Node Lymphocytes B-cells develop in the bone marrow and influence the immune

More information

Large cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s

Large cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of

More information

Non-Hodgkin lymphoma

Non-Hodgkin lymphoma Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma

More information

Lymphoma: The Basics. Dr. Douglas Stewart

Lymphoma: The Basics. Dr. Douglas Stewart Lymphoma: The Basics Dr. Douglas Stewart Objectives What is lymphoma? How common is it? Why does it occur? How do you diagnose it? How do you manage it? How do you follow patients after treatment? What

More information

Head and Neck: DLBCL

Head and Neck: DLBCL Head and Neck: DLBCL Nikhil G. Thaker Chelsea C. Pinnix Valerie K. Reed Bouthaina S. Dabaja Department of Radiation Oncology MD Anderson Cancer Center Case 60 yo male Presented with right cervical LAD

More information

Conflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center

Conflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center What Is Personalized Medicine For Patients With Lymphoma? Conflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center DISCLOSURE I have no potential

More information

LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center

LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells

More information

Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas. Original Policy Date

Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas. Original Policy Date MP 7.03.13 Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013

More information

Peripheral T-cell lymphomas (PTCL) Specified and Unspecified. Eric Van Den Neste Cliniques universitaires Saint-Luc Bruxelles

Peripheral T-cell lymphomas (PTCL) Specified and Unspecified. Eric Van Den Neste Cliniques universitaires Saint-Luc Bruxelles Peripheral T-cell lymphomas (PTCL) Specified and Unspecified Eric Van Den Neste Cliniques universitaires Saint-Luc Bruxelles BHS seminar 12, 07 March 2015 Peripheral T-cell lymphomas (PTCL) Specified and

More information

Peripheral T-Cell Lymphoma. Pro auto. Peter Reimer. Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation

Peripheral T-Cell Lymphoma. Pro auto. Peter Reimer. Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation Peripheral T-Cell Lymphoma Pro auto Peter Reimer Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation Kliniken Essen Süd, Evang. Krankenhaus Essen-Werden ggmbh COSTEM, Berlin 09.09.2011

More information

The treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona

The treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%

More information

Indolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital

Indolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with

More information

Lymphoma- Med A-new drugs and treatments

Lymphoma- Med A-new drugs and treatments Lymphoma- Med A-new drugs and treatments Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Disclosures: Roche, Gilead Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Outline Lymphoma- what is

More information

CAR-T cell therapy pros and cons

CAR-T cell therapy pros and cons CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research

More information

T-cell Lymphomas: Diagnosis and New Agents. Mary Jo Lechowicz Thursday, July 27 Debates and Didactics in Hematology and Oncology

T-cell Lymphomas: Diagnosis and New Agents. Mary Jo Lechowicz Thursday, July 27 Debates and Didactics in Hematology and Oncology T-cell Lymphomas: Diagnosis and New Agents Mary Jo Lechowicz Thursday, July 27 Debates and Didactics in Hematology and Oncology 1 Mature T and NK-cell neoplasms in the WHO Classification 2016 revision

More information

Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphomas

Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphomas Medical Policy Manual Transplant, Policy No. 45.23 Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphomas Next Review: September 2018 Last Review: December 2017 Effective: January 1, 2018 IMPORTANT

More information

NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and

More information

Patient Case Studies & Panel Discussion

Patient Case Studies & Panel Discussion Patient Case Studies & Panel Discussion Panelists: Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center; Ranjana H. Advani, MD, Stanford Cancer Institute; Andrew D. Zelenetz, MD, PhD, Memorial

More information

Prognostic Factors for PTCL. Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Prognostic Factors for PTCL. Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center jmvose@unmc.edu Distribution of 1314 Cases by Consensus Diagnosis International T-Cell Lymphoma Project Vose

More information

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplant for Non-Hodgkin Lymphomas File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplant_for_non_hodgkin_lymphomas

More information

Aggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017

Aggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017 Aggressive NHL and Hodgkin Lymphoma Dr. Carolyn Faught November 10, 2017 What does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks

More information

Hematopoietic Stem-Cell Transplantation for Non-Hodgkin s Lymphomas

Hematopoietic Stem-Cell Transplantation for Non-Hodgkin s Lymphomas Hematopoietic Stem-Cell Transplantation for Non-Hodgkin s Lymphomas Policy Number: 8.01.20 Last Review: 7/2014 Origination: 7/2002 Next Review: 7/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue

More information

Non-Hodgkin Lymphoma in Clinically Difficult Situations

Non-Hodgkin Lymphoma in Clinically Difficult Situations Winship Cancer Institute of Emory University Non-Hodgkin Lymphoma in Clinically Difficult Situations James Armitage, MD Professor, Department of Internal Medicine Joe Shapiro Distinguished Chair of Oncology

More information

During past decades, because of the lack of knowledge

During past decades, because of the lack of knowledge Staging and Classification of Lymphoma Ping Lu, MD In 2004, new cases of non-hodgkin s in the United States were estimated at 54,370, representing 4% of all cancers and resulting 4% of all cancer deaths,

More information

Peripheral T-cell lymphoma. Matt Ahearne Clinical Lecturer, Leicester

Peripheral T-cell lymphoma. Matt Ahearne Clinical Lecturer, Leicester Peripheral T-cell lymphoma Matt Ahearne Clinical Lecturer, Leicester PTCL Objectives To understand the natural history of PTCL To appreciate the importance of accurate diagnosis of PTCL including recent

More information

Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers

Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers Tang et al. (2017) 7:653 DOI 10.1038/s41408-017-0030-y CORRESPONDENCE Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers Open

More information

Recent diagnostic and therapeutic innovations of T-cell-lymphoma. Prof. Nossrat Firusian, Recklinghausen, Germany

Recent diagnostic and therapeutic innovations of T-cell-lymphoma. Prof. Nossrat Firusian, Recklinghausen, Germany Recent diagnostic and therapeutic innovations of T-cell-lymphoma Prof. Nossrat Firusian, Recklinghausen, Germany NODAL Angioimmunoblastic T-cell Lymphoma Peripheral T-cell-Lymphoma Anaplastic Large-cell-Lymphoma

More information

Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies

Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide

More information

Indolent Lymphomas: Current. Dr. Laurie Sehn

Indolent Lymphomas: Current. Dr. Laurie Sehn Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard

More information

Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas

Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas Policy Number: Original Effective Date: MM.07.018 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 03/27/2015 Section:

More information

Update: Non-Hodgkin s Lymphoma

Update: Non-Hodgkin s Lymphoma 2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)

More information

Is there a Role for Upfront Stem Cell Transplantation in Peripheral T-Cell Lymphoma: YES!

Is there a Role for Upfront Stem Cell Transplantation in Peripheral T-Cell Lymphoma: YES! Is there a Role for Upfront Stem ell Transplantation in Peripheral T-ell Lymphoma: YES! Norbert Schmitz Dep. Hematology, Oncology and Stem ell Transplantation AK St. Georg Hamburg, Germany OS in the common

More information

Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta

Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and

More information

Non-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract.

Non-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract. Non-Hodgkin Lymphoma Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract. Protocol revision date: January 2005 No AJCC/UICC staging system Procedures Cytology

More information

What are the hurdles to using cell of origin in classification to treat DLBCL?

What are the hurdles to using cell of origin in classification to treat DLBCL? What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical

More information

Management of high-risk diffuse large B cell lymphoma: case presentation

Management of high-risk diffuse large B cell lymphoma: case presentation Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January

More information

Angioimmunoblastic T-cell lymphoma: nobody knows what to do...

Angioimmunoblastic T-cell lymphoma: nobody knows what to do... Angioimmunoblastic T-cell lymphoma: nobody knows what to do... Felicitas Hitz, Onkologie/Hämatologie St.Gallen SAMO Lucerne 17.9.2011 : Problems PTCL are rare diseases with even rarer subgroups Difficulte

More information

MANAGEMENT OF LYMPHOMAS

MANAGEMENT OF LYMPHOMAS MANAGEMENT OF LYMPHOMAS Challenges & Recommendations F. Chite Asirwa, MD. Internal Medicine Physician Medical Oncologist & Hematologist Director-AMPATH Oncology & Hematology @Kenya Physicians Association

More information

Medical Policy Manual. Date of Origin: May Topic: Hematopoietic Stem-Cell Transplantation for Non- Hodgkin Lymphomas

Medical Policy Manual. Date of Origin: May Topic: Hematopoietic Stem-Cell Transplantation for Non- Hodgkin Lymphomas Medical Policy Manual Topic: Hematopoietic Stem-Cell Transplantation for Non- Hodgkin Lymphomas Section: Transplant Policy No: 45.23 Date of Origin: May 2010 Last Reviewed Date: September 2013 Effective

More information

East Midlands Cancer Network Guidelines for diagnosis and management of mature T cell and NK cell lymphomas (excluding cutaneous T cell lymphoma)

East Midlands Cancer Network Guidelines for diagnosis and management of mature T cell and NK cell lymphomas (excluding cutaneous T cell lymphoma) East Midlands Cancer Network Guidelines for diagnosis and management of mature T cell and NK cell lymphomas (excluding cutaneous T cell lymphoma) Written by: Dr Chris Fox with input from Dr Fiona Miall

More information

Clinical Updates and Issues: T-Cell Lymphomas

Clinical Updates and Issues: T-Cell Lymphomas Clinical Updates and Issues: T-Cell Lymphomas Susan McCall, ANP-BC, AOCNP Memorial Sloan Kettering Cancer Center Learning Objectives Summarize the current and evolving therapeutic options for the treatment

More information

Mantle Cell Lymphoma

Mantle Cell Lymphoma Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.

More information

Recent Advances in the Treatment of Peripheral T-Cell Lymphoma

Recent Advances in the Treatment of Peripheral T-Cell Lymphoma Hematologic Malignancies Recent Advances in the Treatment of Peripheral T-Cell Lymphoma KAMEL LARIBI, a MUSTAPHA ALANI, a CATHERINE TRUONG, b ALIX BAUGIER DE MATERRE c a Department of Hematology, Centre

More information

Aggressive B and T cell lymphomas: Treatment paradigms in 2018

Aggressive B and T cell lymphomas: Treatment paradigms in 2018 Aggressive B and T cell lymphomas: Treatment paradigms in 2018 John P. Leonard M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Associate

More information

Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL

Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin

More information

Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma

Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)

More information

88-year-old Female with Lymphadenopathy. Faizi Ali, MD

88-year-old Female with Lymphadenopathy. Faizi Ali, MD 88-year-old Female with Lymphadenopathy Faizi Ali, MD Clinical History A 88-year-old caucasian female presented to our hospital with the complaints of nausea, vomiting,diarrhea, shortness of breath and

More information

1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes on the next page

1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes on the next page COME HOME Non-Hodgkin pathway development worksheet, v6 September 2014 1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes

More information

Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma (DLBCL) Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives

More information

B Cell Lymphoma: Aggressive

B Cell Lymphoma: Aggressive B Cell Lymphoma: Aggressive UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Ibrutinib approved for mantle cell lymphoma as 2nd line therapy. - Aggressive lymphomas are a group of malignant

More information

Lymphatic system component

Lymphatic system component Introduction Lymphatic system component Statistics Overview Lymphoma Non Hodgkin s Lymphoma Non- Hodgkin's is a type of cancer that originates in the lymphatic system. It is estimated to be the sixth most

More information

Hematopoietic Stem-Cell & Clinical Coverage Policy No: 11A-11 Bone Marrow Transplantation Amended Date: March 1, 2017 For Non-Hodgkin s Lymphoma

Hematopoietic Stem-Cell & Clinical Coverage Policy No: 11A-11 Bone Marrow Transplantation Amended Date: March 1, 2017 For Non-Hodgkin s Lymphoma Hematopoietic Stem-Cell & Clinical Coverage Policy No: 11A-11 Bone Marrow Transplantation Amended Date: March 1, 2017 For Non-Hodgkin s Lymphoma Table of Contents 1.0 Description of the Procedure, Product,

More information

Relapsed/Refractory Hodgkin Lymphoma

Relapsed/Refractory Hodgkin Lymphoma Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage

More information

Hepatic Lymphoma Diagnosis An Algorithmic Approach

Hepatic Lymphoma Diagnosis An Algorithmic Approach Hepatic Lymphoma Diagnosis An Algorithmic Approach Ryan M. Gill, M.D., Ph.D. University of California, San Francisco PLEASE TURN OFF YOUR CELL PHONES Disclosure of Relevant Financial Relationships USCAP

More information

Overview of Cutaneous Lymphomas: Diagnosis and Staging. Lauren C. Pinter-Brown MD, FACP Health Sciences Professor of Medicine and Dermatology

Overview of Cutaneous Lymphomas: Diagnosis and Staging. Lauren C. Pinter-Brown MD, FACP Health Sciences Professor of Medicine and Dermatology Overview of Cutaneous Lymphomas: Diagnosis and Staging Lauren C. Pinter-Brown MD, FACP Health Sciences Professor of Medicine and Dermatology Definition of Lymphoma A cancer or malignancy that comes from

More information

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus

More information

OSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD

OSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD OSCO/OU ASH-SABC Review Lymphoma Update Mohamad Cherry, MD Outline Diffuse Large B Cell Lymphoma Double Hit Lymphoma Follicular and Indolent B Cell Lymphomas Mantle Cell Lymphoma T Cell Lymphoma Hodgkin

More information

PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma

PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer

More information

Interesting case in lymphoma. Kitsada Wudhikarn, MD Division of Hematology, Department of Medicine Faculty of Medicine, Chulalongkorn University

Interesting case in lymphoma. Kitsada Wudhikarn, MD Division of Hematology, Department of Medicine Faculty of Medicine, Chulalongkorn University Interesting case in lymphoma Kitsada Wudhikarn, MD Division of Hematology, Department of Medicine Faculty of Medicine, Chulalongkorn University Eosinophilia Benign reactive etiologies 1. Allergy 2. Infection

More information

Should peripheral T-cell lymphoma be treated by autologous or allogeneic SCT?

Should peripheral T-cell lymphoma be treated by autologous or allogeneic SCT? Francesco d Amore, MD, PhD Dept. Of Hematology Aarhus University Hospital, Aarhus, Denmark Should peripheral T-cell lymphoma be treated by autologous or allogeneic SCT? Disclosure of Interest: Nothing

More information

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma

More information

WHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia

WHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia Blood Malignancies-II Prof. Dr. Herman Hariman, a Ph.D, SpPK (KH). Prof. Dr. Adikoesoema Aman, SpPK (KH) Dept. of Clinical Pathology, School of Medicine, University of North Sumatra WHO classification

More information

2012 by American Society of Hematology

2012 by American Society of Hematology 2012 by American Society of Hematology Common Types of HIV-Associated Lymphomas DLBCL includes primary CNS lymphoma (PCNSL) Burkitt Lymphoma HIV-positive patients have a 60-200 fold increased incidence

More information

Immune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust

Immune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint

More information

Treatment outcomes of IMEP as a front-line chemotherapy for patients with peripheral T-cell lymphomas

Treatment outcomes of IMEP as a front-line chemotherapy for patients with peripheral T-cell lymphomas BLOOD RESEARCH VOLUME 51 ㆍ NUMBER 3 September 2016 ORIGINAL ARTICLE Treatment outcomes of IMEP as a front-line chemotherapy for patients with peripheral T-cell lymphomas Ji Young Lee 1, Sang Min Lee 1,

More information

Clinical Update. Educational Objectives After completing this activity, the participant should be better able to:

Clinical Update. Educational Objectives After completing this activity, the participant should be better able to: Target Audience This activity has been designed to meet the educational needs of oncologists, hematologists, and nurses involved in the management of patients with peripheral T-cell lymphoma (PTCL). Statement

More information

Clinical Roundtable Monograph

Clinical Roundtable Monograph Clinical Roundtable Monograph C l i n i c a l A d v a n c e s i n H e m a t o l o g y & O n c o l o g y A u g u s t 2 0 1 1 Current Treatment of Peripheral T-Cell Lymphoma Moderator Discussants Steven

More information

Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:

Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum

More information

ORIGINAL ARTICLE CHARACTERISTICS AND OUTCOMES OF ANAPLASTIC LARGE CELL LYMPHOMA PATIENTS-A SINGLE CENTRE EXPERIENCE

ORIGINAL ARTICLE CHARACTERISTICS AND OUTCOMES OF ANAPLASTIC LARGE CELL LYMPHOMA PATIENTS-A SINGLE CENTRE EXPERIENCE ORIGINAL ARTICLE CHARACTERISTICS AND OUTCOMES OF ANAPLASTIC LARGE CELL LYMPHOMA PATIENTS-A SINGLE CENTRE EXPERIENCE Sohail Athar, Neelam Siddiqui, Abdul Hameed Department of Medical Oncology, Shaukat Khanum

More information

Immunopathology of Lymphoma

Immunopathology of Lymphoma Immunopathology of Lymphoma Noraidah Masir MBBCh, M.Med (Pathology), D.Phil. Department of Pathology Faculty of Medicine Universiti Kebangsaan Malaysia Lymphoma classification has been challenging to pathologists.

More information

Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)

Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail

More information

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating

More information

NON-HODGKIN LYMPHOMA TREATMENT REGIMENS: Peripheral T-Cell Lymphoma (Part 1 of 5)

NON-HODGKIN LYMPHOMA TREATMENT REGIMENS: Peripheral T-Cell Lymphoma (Part 1 of 5) Peripheral T-Cell Lymphoma (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer

More information

ESMO DOUBLE-HIT LYMPHOMAS

ESMO DOUBLE-HIT LYMPHOMAS ESMO DOUBLE-HIT LYMPHOMAS Professor Dr. med. Georg Lenz Director Department of Hematology and Oncology Universitätsklinikum Münster, Germany OVERVIEW Definition of double-hit lymphomas Introduction in

More information

2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용

2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas

More information

Aggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV

Aggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV Aggressive lymphomas ASH 2015 Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV CHOP 1992 2002 R-CHOP For DLBCL High dose chemo With PBSCT Aggressive lymphomas 1.DLBCL 2.Primary Mediastinal Lymphoma 3.CNS

More information

10/31/2017. Immunodeficiencies. Outline. Discuss EBV. Non-destructive Polymorphic Monomorphic Therapies Challenges

10/31/2017. Immunodeficiencies. Outline. Discuss EBV. Non-destructive Polymorphic Monomorphic Therapies Challenges I have no financial disclosures Joo Y. Song, MD Assistant Professor of Clinical Pathology City of Hope National Medical Center Immunodeficiencies Outline Transplant Congenital Autoimmunity T-cell/immune

More information

Development of Mogamulizumab, a defucosylated anti-ccr4 humanized monoclonal antibody

Development of Mogamulizumab, a defucosylated anti-ccr4 humanized monoclonal antibody New Drugs in Hematology Development of Mogamulizumab, a defucosylated anti-ccr4 humanized monoclonal antibody Michinori Ogura, MD, PhD Department of Hematology Tokai Central Hospital Bologna, Royal Hotel

More information

Differential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital

Differential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Differential diagnosis of hematolymphoid tumors composed of medium-sized cells Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Lymphoma classification Lymphoma diagnosis starts with morphologic

More information

TCH em Linfomas T. Fábio R. Kerbauy

TCH em Linfomas T. Fábio R. Kerbauy TCH em Linfomas T Fábio R. Kerbauy T-Cell Lymphomas ( 6000 cases/y USA) J Clin Oncol 2008;26:4124-4130 Proportion T-cell lymphomas prognosis by subtipe 1.0 0.9 0.8 0.7 0.6 0.5 ALCL ALK+ 0.4 0.3 0.2 0.1

More information

MANTLE CELL LYMPHOMA

MANTLE CELL LYMPHOMA MANTLE CELL LYMPHOMA CLINICAL CASE PRESENTATION Martin Dreyling Medizinische Klinik III LMU München Munich, Germany esmo.org Multicenter Evaluation of MCL Annency Criteria fulfilled event free interval

More information

A CASE OF PRIMARY THYROID LYMPHOMA. Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey

A CASE OF PRIMARY THYROID LYMPHOMA. Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey A CASE OF PRIMARY THYROID LYMPHOMA Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey 38 year old female She recognized a mass in her right neck

More information

Harmesh Naik, MD. GME Presentation to Family Practice Residents October 16, 2013.

Harmesh Naik, MD. GME Presentation to Family Practice Residents October 16, 2013. Harmesh Naik, MD. GME Presentation to Family Practice Residents October 16, 2013. Lymphoma: Lympho-proliferative disorders arising from lymphocytes Heterogeneous group of disorders Differing patterns of

More information

Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009

Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009 Treatment of DLBCL Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009 Non-hodgkin lymphomas DLBCL Most common NHL subtype throughout the world many other types of lymphoma with striking geographic variations

More information

Lymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham

Lymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham Lymphoid Neoplasms Sylvie Freeman Department of Clinical Immunology, University of Birmingham Incidence of Haematological Malignancies UK2001 (CRUK) Malignancy New Cases All Cancers 271,000 Leukaemia 6,760

More information

Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA

Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Objectives Describe the current standard approach for patients with relapsed/refractory

More information

Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients

Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France

More information

LEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University

LEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish

More information

Bendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service

Bendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine for Hodgkin lymphoma Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine in Hodgkin lymphoma Bifunctional molecule Nitrogen mustard component (meclorethamine)

More information

What s new on the horizon in T-cell lymphoma Elaine S Jaffe National Cancer Institute, Bethesda MD

What s new on the horizon in T-cell lymphoma Elaine S Jaffe National Cancer Institute, Bethesda MD What s new on the horizon in T-cell lymphoma Elaine S Jaffe National Cancer Institute, Bethesda MD WHO classification: where are we today? Of 12 monographs planned for 4 th Edition Bluebook series, only

More information

11/2/2017. Immunodeficiencies. Joo Y. Song, MD Assistant Professor of Clinical Pathology. I have no financial disclosures.

11/2/2017. Immunodeficiencies. Joo Y. Song, MD Assistant Professor of Clinical Pathology. I have no financial disclosures. I have no financial disclosures Joo Y. Song, MD Assistant Professor of Clinical Pathology City of Hope National Medical Center Immunodeficiencies Transplant Autoimmunity Drugs T-cell dysfunction (Age,

More information